Ko Tai-Ming, Wong Chih-Shung, Wu Jer-Yuarn, Chen Yuan-Tsong
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
Department of Anesthesiology, Cathay General Hospital, Taipei, Taiwan.
Acta Anaesthesiol Taiwan. 2016 Mar;54(1):24-30. doi: 10.1016/j.aat.2016.02.001. Epub 2016 Mar 11.
Pharmacogenomics aims to unravel the way that human genetic variation affects drug efficacy and toxicity. Genome-wide association studies and candidate gene findings suggest that genetic approaches may help choose the most appropriate drug and dosage while preventing adverse drug reactions (ADRs). Pain is an unpleasant feeling that usually results from tissue damage. The management of different types of pain (acute, chronic, inflammatory, neuropathic, or cancer) is challenging. Currently, drug intervention is the first-line therapy for resolving pain. However, differences in drug efficacy between individuals are common with pain medications. Moreover, some patients experience ADRs after being treated with specific pain drugs. This review discusses the use of drugs for pain management in the context of the recent pharmacogenomic studies on ADRs and drug efficacy.
药物基因组学旨在揭示人类基因变异影响药物疗效和毒性的方式。全基因组关联研究和候选基因研究结果表明，基因方法可能有助于选择最合适的药物和剂量，同时预防药物不良反应（ADR）。疼痛是一种通常由组织损伤引起的不愉快感觉。对不同类型疼痛（急性、慢性、炎症性、神经性或癌性疼痛）的管理具有挑战性。目前，药物干预是缓解疼痛的一线治疗方法。然而，个体之间药物疗效的差异在止痛药中很常见。此外，一些患者在接受特定止痛药治疗后会出现药物不良反应。本综述在近期关于药物不良反应和药物疗效的药物基因组学研究背景下，讨论了用于疼痛管理的药物的使用情况。
